Advances of Osteosarcoma Models for Drug Discovery and Precision Medicine

Tan, Linyun; Wang, Yitian; Hu, Xin; Du, Guifeng; Tang, Xiaodi; Min, Li

doi:10.3390/biom13091362

Cited by 2 publications

(1 citation statement)

References 102 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Osteosarcoma is a primary malignant bone tumour that poses a significant clinical challenge (Tan et al, 2023). Over the last two decades, the incidence of malignant bone tumours, especially osteosarcoma, has increased (Xu et al, 2023).…”

Section: Introductionmentioning

confidence: 99%

Cucurbitacin B modulates M2 macrophage differentiation and attenuates osteosarcoma progression via PI3K/AKT pathway

Wu,

Ma,

et al. 2024

Phytotherapy Research

View full text Add to dashboard Cite

Osteosarcoma is a common malignant bone tumour characterised by an aggressive metastatic potential. The tumour microenvironment, particularly the M2‐polarised macrophages, is crucial for tumour progression. Cucurbitacin B (CuB), a triterpenoid derivative, is recognised for its anti‐inflammatory and antitumour properties. This study investigates CuB and its effect on M2 macrophage differentiation and osteosarcoma progression, aiming to contribute to new treatment strategies. In vitro, THP‐1 monocytes were stimulated with PMA, IL‐13 and IL‐4 to induce differentiation into M2 macrophages. Additionally, the influence of CuB on the proliferation, migration and invasion of osteosarcoma cells in the context of M2 macrophages was scrutinised. Crucial signalling pathways, especially the PI3K/AKT pathway, affected by CuB were identified and validated. In vivo, the osteosarcoma model was employed to gauge the effects of CuB on tumour weight, lung metastasis, angiogenesis, cell proliferation and M2 macrophage markers. The results showed that CuB inhibited M2 macrophage differentiation, leading to reduced proliferation, migration and invasion of osteosarcoma cells. CuB manifested an inhibitory effect on the PI3K/AKT pathway during the differentiation of M2 macrophages. In mouse models, CuB markedly reduced the tumour weight and the number of lung metastases. It also reduced the expression of angiogenesis and cell proliferation markers in tumour tissues, decreased the quantity of M2 macrophages and their associated markers and pathway proteins. In conclusion, CuB impedes osteosarcoma progression by inhibiting M2 macrophage differentiation via the PI3K/AKT pathway, presenting the potential for therapeutic advancements in osteosarcoma treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

Cucurbitacin B modulates M2 macrophage differentiation and attenuates osteosarcoma progression via PI3K/AKT pathway

Wu,

Ma,

et al. 2024

Phytotherapy Research

View full text Add to dashboard Cite

show abstract

From Spheroids to Bioprinting: A Literature Review on Biomanufacturing Strategies of 3D In Vitro Osteosarcoma Models

Domingues,

Silva,

Sanjuan‐Alberte

2024

Advanced Therapeutics

View full text Add to dashboard Cite

Osteosarcoma (OS) is a rare primary malignant bone cancer affecting mainly young individuals. Treatment typically consists of chemotherapy and surgical tumor resection, which has undergone few improvements since the 1970s. This therapeutic approach encounters several limitations attributed to the tumor's inherent chemoresistance, marked heterogeneity and metastatic potential. Therefore, the development of in vitro platforms that closely mimic the OS pathophysiology is crucial to understand tumor progression and discover effective anticancer therapeutics. Contrary to 2D monolayer cultures and animal models, 3D in vitro platforms show promise in replicating the 3D tumor macrostructure, cell‐cell and cell‐extracellular matrix interactions. This review provides an overview of the biomanufacturing strategies employed in developing 3D in vitro OS models, highlighting their role in replicating different aspects of OS and improving OS anticancer research and drug screening. A variety of 3D in vitro models are explored, including both scaffold‐free and scaffold‐based models, encompassing cell spheroids, hydrogels, and innovative approaches like electrospun nanofibers, microfluidic devices and bioprinted constructs. By examining the distinctive features of each model type, this review offers insights into their potential transformative impact on the landscape of OS research and therapeutic innovation, addressing the challenges and future directions of 3D in vitro OS modeling.

show abstract

Advances of Osteosarcoma Models for Drug Discovery and Precision Medicine

Cited by 2 publications

References 102 publications

Cucurbitacin B modulates M2 macrophage differentiation and attenuates osteosarcoma progression via PI3K/AKT pathway

Cucurbitacin B modulates M2 macrophage differentiation and attenuates osteosarcoma progression via PI3K/AKT pathway

From Spheroids to Bioprinting: A Literature Review on Biomanufacturing Strategies of 3D In Vitro Osteosarcoma Models

Contact Info

Product

Resources

About